ArticlePloS one2013
RAPID-SELEX for RNA aptamers.
Article in PloS one, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed.
- Antibody-aptamer Complementation: Advancing Biosensing for Disease Monitoring.Current topics in medicinal chemistry · 2026Review
- Therapeutic Oligonucleotides for Neurodegenerative Diseases: Aptamer Strategies and Clay Nanoparticle-Based Delivery.Chemical record (New York, N.Y.) · 2025Review
- SELEX identifies high-affinity RNA targets for chromatin-binding proteins PARP1 and MeCP2.iScience · 2025Article
- Single-step discovery of high-affinity RNA ligands by UltraSelex.Nature chemical biology · 2025Article
- Therapeutic Applications of Aptamers.International journal of molecular sciences · 2024Review
- A modified SELEX approach to identify DNA aptamers with binding specificity to the major histocompatibility complex presenting ovalbumin model antigen.RSC advances · 2023Article
- Advanced cancer targeting using aptamer functionalized nanocarriers for site-specific cargo delivery.Biomaterials research · 2023Review
- Article
- Aptamer Applications in Neuroscience.Pharmaceuticals (Basel, Switzerland) · 2021Review
- Implementation of High-Throughput Sequencing (HTS) in Aptamer Selection Technology.International journal of molecular sciences · 2020Review
- Developments of Riboswitches and Toehold Switches for Molecular Detection-Biosensing and Molecular Diagnostics.International journal of molecular sciences · 2020Review
- Predicting Future Prospects of Aptamers in Field-Effect Transistor Biosensors.Molecules (Basel, Switzerland) · 2020Article
- Updates on Aptamer Research.International journal of molecular sciences · 2019Review
- Molecular Application of Aptamers in the Diagnosis and Treatment of Cancer and Communicable Diseases.Pharmaceuticals (Basel, Switzerland) · 2018Review
- Aptamers in HIV research diagnosis and therapy.RNA biology · 2018Review
- Selection and Identification of Skeletal-Muscle-Targeted RNA Aptamers.Molecular therapy. Nucleic acids · 2018Article
- Application of the Open qPCR Instrument for the in Vitro Selection of DNA Aptamers against Epidermal Growth Factor Receptor and Drosophila C Virus.ACS combinatorial science · 2018Article
- Aptamer Technology: Adjunct Therapy for Malaria.Biomedicines · 2017Review
- Highly Multiplexed RNA Aptamer Selection using a Microplate-based Microcolumn Device.Scientific reports · 2016Article
- Revealing protein-lncRNA interaction.Briefings in bioinformatics · 2016Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Aptamers are high-affinity ligands selected from DNA or RNA libraries via SELEX, a repetitive in vitro process of sequential selection and amplification steps. RNA SELEX is more complicated than DNA SELEX because of the additional transcription and reverse transcription steps. Here, we report a new selection scheme, RAPID-SELEX (RNA Aptamer Isolation via Dual-cycles SELEX), that simplifies this process by systematically skipping unnecessary amplification steps. Using affinity microcolumns, we were able to complete a multiplex selection for protein targets, CHK2 and UBLCP1, in a third of the time required for analogous selections using a conventional SELEX approach. High-throughput sequencing of the enriched pools from both RAPID and SELEX revealed many identical candidate aptamers from the starting pool of 5 × 10(15) sequences. For CHK2, the same sequence was preferentially enriched in both selections as the top candidate and was found to bind to its respective target. These results demonstrate the efficiency and, most importantly, the robustness of our selection scheme. RAPID provides a generalized approach that can be used with any selection technology to accelerate the rate of aptamer discovery, without compromising selection performance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.